| Main Intermediates | |||
| Product Name | Specification |
Approved |
CAS No. |
| DHEA(Prasterone) | Min99.0% | DMF/WC | 53-43-0 |
| DHEA Acetate(Prasterone Acetate) | Min99.0% | DMF | 853-23-6 |
| Epiandrosterone | Min99.0% | TP | 481-29-8 |
| 16-DPA | Min99.0% | TP | 979-02-2 |
| Pregnenolone acetate | Min98.0% | TP/ Kosher | 1778-02-5 |
| Pregnenolone | Min99.0% | TP/Kosher | 145-13-1 |
| 16α-Hydroxyprednisolone | Min99.0% | DMF | 13951-70-7 |
| Estrone | USP36 | TP | 53-16-7 |
| Flumethasone | Min98.0% | TP | 2135-17-3 |
17a-Hydroxyprogesterone is an endogenous progesteroid hormone similar to progesterone.
21-Acetoxy-11β-hydroxypregna-1,4,16-triene-3,20-dione is an intermediate in the synthesis of Budesonide (B689490) related derivatives.
DHEA Acetate(Prasterone Acetate) is the intermediate of DHEA(prasterone).
Epiandrosterone is a steroid hormone with weak androgenic activity. It is a metabolite of testosterone and dihydrotestosterone (DHT).
17a-Hydroxyprogesterone Acetate is an endogenous progesteroid hormone similar to progesterone.
Abiraterone is a steroidal cytochrome P 450 17α-hydroxylase-17,20-lyase inhibitor (CYP17), It is used in combination with prednisone to treat patients with metastatic castration-resistant prostate cancer (prostate cancer that is resistant to medical or surgical treatments that lower testosterone and has already spread to other parts of the body) and metastatic high-risk castration-sensitive prostate cancer.